5 Most Discussed Stocks – CLA, AVZ, AUZ, BD1 and MXC

0
298

The ASX started the week on a lower note as there are negative signals from the US and China trade war, however, few of the resources and health care stocks came under discussion as they traded in green. Let’s take a look at these stocks holding on:

CELSIUS RESOURCES LIMITED (ASX: CLA) – The company requests that a voluntary suspension continued to be placed on all its listed securities. It has also completed a positive scoping study on Opuwa cobalt project’s completion. As compared to 2017 loss of $781,822 after providing for income tax and eliminating non-controlling equity interests the loss of the consolidated entity amounted to $2,790,788. No dividends were paid or declared since the start of the financial year, no dividend has been recommended. As compared to 2017 value of $3,826,418, the consolidated entity’s net working capital, is a net current asset of $13,382,201 which represents the ability to pay short term loan obligations. The stock traded flat at a market price of $0.105 as at November 5, 2018 and has undergone a performance change of 47.89% over the past 12 months.  

AVZ MINERALS LIMITED (ASX: AVZ) – The AVZ’s scoping study highlights strong economic potential of Manono Lithium Project. The revenue of the company increased to $169,121 in 2018 from $20,432 in 2017. At the end of the financial year June 30, 2018, the company had a cash and cash equivalents balance of $16.34 million with nil debt representing a healthy balance sheet. The earnings per share (EPS) of -0.003 AUD restrains the profitability of the company. For the Manono lithium project, new work has commenced on 5Mtpa and 10Mtpa scoping studies. The stock traded higher at a market price of $0.082 as at November 5, 2018 and has undergone a performance change of 95.68% since the inception of the stock.

AUSTRALIAN MINES LIMITED (ASX: AUZ) – To unlock growth potential for nickel and cobalt resources extensional drilling at Sconi Project continues for further better results. The company recently go aboard on a 50,000-meter Resource Expansion drilling program at Sconi. With minimal dilution to the Company’s shareholders, Australian Mines has moved to acquire 100% ownership of all three of its battery metals projects over the past twelve months. Through the ongoing exploration of tenements, the company incurs expenditure, no return has been generated as the company is yet to provide income by moving into production. The stock traded higher at a market price of $0.053 as at November 5, 2018 and has undergone a performance change of 4.17% since the inception of the stock.

BARD1 LIFE SCIENCES LIMITED (ASX: BD1) – The China National Intellectual Property Administration, granted chinese patent number entitled ‘BARD1 isoforms in lung and colorectal cancer and its use thereof. The net assets of the consolidated entity at 30 June 2018 totaled $1,130,487 as compared to June 30, 2017 of $257,937. Total company assets at 30 June 2018 are of $1,453,137 and at 30 June 2017 are of $726,896. The cash and cash equivalents for the consolidated entity had increased to $1,445,657 as at 30 June 2018 as compared to 30 June 2017 of $650,051 with no debt facility for improved operational and investing activities. Board recommended no dividend to be declared, provided for or paid in respect of the current year or previous year. The stock has an earnings per share of -0.003 AUD As at November 5, 2018, the stock of Bard1 traded higher after few lows at a market price of $0.036, it has seen a performance change of 33.33% over the past 5 years.

MGC PHARMACEUTICALS LTD (ASX: MXC) – To create an online platform dedicated to providing information and education on medicinal cannabis and epilepsy, MGC Pharmaceuticals Ltd has partnered with Epilepsy Action Australia. The company expects to generate in excess of $1 million in annualized revenue. CannEpil is an orally-administered medical cannabis treatment, which accounts for about 30 percent of all epilepsy cases, for refractory epilepsy or drug-resistant. As at June 30, 2018, the revenue has increased significantly to $296,811 from $120,242 in 2017 which is up by 146%. At the end of the financial year ending June 30, 2018, the cash and cash equivalents has been $9.86 million with zero debt which represents healthy balance sheet. The stock of MGC has traded flat at a market price of $0.051, as at November 5, 2018, and since the inception period it has witnessed a performance change of 75.15%.

price chartPrice Chart for 5 stocks, Source: Thomson Reuters.


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.